DNA vaccines expressing pneumococcal surface protein A (PspA) elicit protection levels comparable to recombinant protein

Journal of Medical Microbiology
Daniela M FerreiraL C C Leite

Abstract

Pneumococcal surface protein A (PspA) is a promising candidate for the development of cost-effective vaccines against Streptococcus pneumoniae. In the present study, BALB/c mice were immunized with DNA vaccine vectors expressing the N-terminal region of PspA. Animals immunized with a vector expressing secreted PspA developed higher levels of antibody than mice immunized with the vector expressing the antigen in the cytosol. However, both immunogens elicited similar levels of protection against intraperitoneal challenge. Furthermore, immunization with exactly the same fragment in the form of a recombinant protein, with aluminium hydroxide as an adjuvant, elicited even higher antibody levels, but this increased humoral response did not correlate with enhanced protection. These results show that DNA vaccines expressing PspA are able to elicit protection levels comparable to recombinant protein, even though total anti-PspA IgG response is considerably lower.

References

Dec 31, 1997·The Journal of Experimental Medicine·R S ChuC V Harding
Apr 16, 2003·The Journal of Infectious Diseases·Maria-Cristina C BrandileoneRobert Austrian
Sep 27, 2003·Methods : a Companion to Methods in Enzymology·Nicole A Doria-Rose, Nancy L Haigwood
May 20, 2004·Vaccine·D BogaertR de Groot
Jul 27, 2004·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·C R R RamosP L Ho

❮ Previous
Next ❯

Citations

Mar 10, 2015·Applied Microbiology and Biotechnology·Agnieszka WyszyńskaElżbieta Katarzyna Jagusztyn-Krynicka
May 18, 2017·Frontiers in Microbiology·Naeem Khan, Arif T Jan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.